Clinical trials: Cardiovascular Events
Diabetic Retinopathy
Lowering Events in Non-proliferative Retinopathy in Scotland
LENS is a streamlined multicentre randomised placebo-controlled parallel-group trial investigating the effect of fenofibrate treatment on the progression of diabetic retinopathy/maculopathy.
- Trial name
- LENS (NCT03439345)
- Testing
- Fenofibrate 145 mg
- Where
- 16 sites in United Kingdom
- Volunteers
- 1,151 people
- Sponsor
- University of Oxford
COVID-19, Venous Thromboembolism
Prevention of Arteriovenous Thrombotic Events in Critically-Ill COVID-19 Patients Trial
The researchers wanted to learn how to help sick patients who are in the hospital because of COVID-19. They are trying to find out the best way that is safe to stop blood clots that could be dangerous from forming in patients…
- Conditions
- COVID-19, Venous Thromboembolism, Arterial Thrombosis
- Trial name
- COVID-PACT (NCT04409834)
- Testing
- Unfractionated Heparin IV, Enoxaparin 1 mg/kg, Clopidogrel
- Where
- United States
- Volunteers
- 390 people
- Sponsor
- The TIMI Study Group
Heart Failure, Congestive
Meta-Iodobenzylguanidine Scintigraphy Imaging in Patients With Heart Failure and Control Subjects Without Cardiovascular Disease
The study is designed to study the utility of 123I-mIBG as a diagnostic imaging agent to predict cardiac outcomes in subjects with heart failure and in comparison to subjects without cardiovascular disease.
- Trial name
- NCT00126425
- Testing
- 123I-mIBG (meta-iodobenzylguanidine)
- Where
- United States
- Volunteers
- 587 people, healthy volunteers welcome
- Sponsor
- GE Healthcare
Obesity, Overweight
Cardiovascular Outcomes Study of Naltrexone SR/Bupropion SR in Overweight and Obese Subjects With Cardiovascular Risk Factors (The Light Study)
The purpose of this study is to determine the effects of NB relative to placebo on major adverse cardiovascular events (MACE) such as cardiovascular death, non-fatal myocardial infarction, and non-fatal stroke in overweight and…
- Trial name
- NCT01601704
- Testing
- NB32, PBO, Weight Management Program
- Where
- 224 sites in United States
- Volunteers
- 8,910 people
- Sponsor
- Orexigen Therapeutics, Inc
Heart Failure, Type 2 Diabetes Mellitus
Effect of Sotagliflozin on Cardiovascular Events in Participants With Type 2 Diabetes Post Worsening Heart Failure (SOLOIST-WHF Trial)
Primary Objective: To compare the effect of sotagliflozin to placebo on the total occurrences of cardiovascular (CV) death, hospitalization for heart failure (HHF), and urgent visit for heart failure (HF) in hemodynamically…
- Trial name
- NCT03521934
- Testing
- Sotagliflozin
- Where
- 466 sites in United States, Argentina and 30 more
- Volunteers
- 1,222 people
- Sponsor
- Lexicon Pharmaceuticals
Smoking Cessation, Acute Coronary Syndrome
Post Acute Coronary Event Smoking Study
Smoking and depressed mood are both predictive of mortality following Acute Coronary Syndrome. However, to date, no counseling treatment has been designed to target smoking cessation and manage mood in this population.
- Trial name
- PACES (NCT01964898)
- Testing
- Behavioral Activation (BA), Standard Smoking Cessation Counseling, Nicotine patch
- Where
- United States
- Volunteers
- 65 people
- Sponsor
- The Miriam Hospital
Non ST Segment Elevation Acute Coronary Syndrome
Different LD of Ticagrelor for Antiplatelet Effect in Patients With Non-ST-segment Elevation ACS Undergoing PCI
It is designed to test the hypothesis that high loading dose(360mg) ticagrelor versus conventional loading dose(180mg) will result in a higher inhibition of platelet aggregation(IPA) without increasing the bleeding events.
- Trial name
- NCT01962428
- Testing
- ticagrelor
- Where
- 2 sites in China
- Volunteers
- 250 people
- Sponsor
- General Hospital of Chinese Armed Police Forces
Type 2 Diabetes Mellitus
Does Saxagliptin Reduce the Risk of Cardiovascular Events When Used Alone or Added to Other Diabetes Medications
The purpose of this study is to determine whether saxagliptin can reduce the risk of cardiovascular events when used alone or added to other diabetes medications
- Trial name
- SAVOR- TIMI 53 (NCT01107886)
- Testing
- Saxagliptin
- Where
- 536 sites in United States, Argentina and 25 more
- Volunteers
- 18,206 people
- Sponsor
- AstraZeneca
Cardiovascular Disease, Peripheral Artery Disease
Platelet Activity in Vascular Surgery and Cardiovascular Events
Pathological and clinical studies have consistently demonstrated that abnormalities in thrombosis and hemostasis play a major role in the pathogenesis of atherosclerosis and atherothrombosis.
- Conditions
- Cardiovascular Disease, Peripheral Artery Disease, Critical Limb Ischemia
- Trial name
- PACE (NCT02106429)
- Where
- United States
- Volunteers
- 246 people
- Sponsor
- NYU Langone Health
Cardiac Arrest
Removing Surrogates' Uncertainty to Reduce Fear and Anxiety After Cardiac Events
The goal of this study is to test the feasibility and acceptability of an informational website to reduce uncertainty, psychological distress, and caregiver burden among close family members of cardiac arrest patients.
- Trial name
- RESURFACE (NCT06048068)
- Testing
- Educational Informational Platform
- Where
- United States
- Volunteers
- 53 people
- Sponsor
- Columbia University
Stable Angina
Aspirin Resistance and Percutaneous Coronary Intervention (PCI)
The objective of this study is to evaluate if aggressive antiplatelet therapy would reduce ischemic events in aspirin (ASA) resistant patients after percutaneous coronary intervention (PCI).
- Trial name
- RESIST (NCT01103440)
- Testing
- Intravenous Glycoprotein inhibitor + ASA, Clopidogrel, Antiplatelet Therapy (ASA, Clopidogrel)
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- Icahn School of Medicine at Mount Sinai
Acute Coronary Syndrome
A Phase 3 Clinical Outcomes Study to Compare the Incidence of Major Adverse Cardiovascular Events in Subjects Presenting With Acute Coronary Syndrome Treated With Losmapimod Compared to Placebo (LATITUDE-TIMI 60)
Losmapimod is a new anti-inflammatory medication which potentially may benefit patients with Acute Coronary Syndrome, (ACS), a condition which includes heart attack.
- Trial name
- LATITUDE (NCT02145468)
- Testing
- Losmapimod 7.5 mg twice daily, Standard therapy
- Where
- 341 sites in United States, Argentina and 32 more
- Volunteers
- 3,503 people
- Sponsor
- GlaxoSmithKline
Blood Pressure, Hypertension
PACESETTER: Program to Avoid Cerebrovascular Events Through Systematic Electronic Tracking and Tailoring of an Eminent Risk-factor
Program to Avoid Cerebrovascular Events through Systematic Electronic Tracking and Tailoring of an Eminent Risk-factor (PACESETTER) aims to assess the incorporation of its stroke intervention into 2 safety net/academic health…
- Conditions
- Blood Pressure, Hypertension, Mhealth
- Trial name
- NCT03401489
- Testing
- PACESETTER
- Where
- 4 sites in United States
- Volunteers
- 120 people
- Sponsor
- Northern California Institute of Research and Education